Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Ardelyx Inc (NQ: ARDX )

5.160 USD -0.130 (-2.46%)
Official Closing Price Updated: 4:01 PM EDT, Oct 23, 2020 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 211,700
Open 5.340
Bid (Size) 5.050 (3)
Ask (Size) 5.450 (7)
Prev. Close 5.290
Today's Range 5.110 - 5.445
52wk Range 4.220 - 8.815
Shares Outstanding 60,103,568
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Ardelyx and Kyowa Kirin Highlight New Data Supporting the Clinical Safety and Efficacy of First-In-Class, Phosphate Absorption Inhibitor Tenapanor at ASN's Kidney Week 2020
--Data presented across five posters continue to support the foundational role tenapanorcould play in the treatment of hyperphosphatemia-- 
From PR Newswire
Ardelyx Launches 'Can We Do Better?' Campaign at ASN's Kidney Week 2020
--Campaign highlights Ardelyx commitment to advance the science of phosphate absorption to address significant unmet needs in the current treatment of hyperphosphatemia-- 
From PR Newswire

Performance

YTD
-29.80%
-29.80%
1 Month
-7.03%
-7.03%
3 Month
-18.35%
-18.35%
6 Month
-31.47%
-31.47%
1 Year
+6.39%
+6.39%

More News

Read More
Ardelyx Announces Data Supporting Efficacy and Safety of Tenapanor, a First-in-Class Phosphate Absorption Inhibitor, to be Presented at ASN's Kidney Week 2020
From PR Newswire
Ardelyx Announces FDA Acceptance for Filing of its New Drug Application of Tenapanor for the Control of Serum Phosphorus in Adult Patients with CKD on Dialysis
From PR Newswire
Ardelyx to Participate in Three Upcoming Investor Conferences in September
From PR Newswire
Ardelyx Reports Second Quarter 2020 Financial Results and Recent Business Highlights
From PR Newswire
Ardelyx Selected as a Finalist in the Fierce Innovation Awards for the Development of its First-in-Class Product Candidate Tenapanor
From PR Newswire
Ardelyx Announces Submission of New Drug Application to the U.S. FDA for Tenapanor for the Control of Serum Phosphorus in Adult Patients with CKD on Dialysis
From PR Newswire
Ardelyx Announces Positive Second Data Analysis from Ongoing NORMALIZE Phase 4 Study Evaluating Tenapanor in CKD Patients on Dialysis
From PR Newswire
Ardelyx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From PR Newswire
Ardelyx Appoints Veteran Biopharma Executive, Justin Renz, as Chief Financial Officer
From PR Newswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.